Galecto, Inc. (GLTO): Company Cash Volume

Symbol and logo of brand Galecto Corp (GLTO)

Galecto, Inc. is developing a proprietary patent system of galectin inhibitors, focusing on cancer and organ fibrosis therapies. The company is currently prioritizing organic asset growth and local partnerships, temporarily limiting large-scale transactions. Analyzing the cash balance on GURU.Markets, we see that 0.01 determines the current value of this metric, confirming the firm's liquidity level.

GLTO - Galecto Corp Company Cash Volume over the range 07/04/2022 - 03/10/2026

Summary analytical data breakdowns for Galecto (GLTO)

- stock value and consensus price forecast:
Fundamental company analysis:Galecto Corp GLTO
Brand item of galecto.com

This metric reflects the volume of liquid assets required to ensure the issuer's operational stability. By analyzing the cash balance chart, an investor assesses the business's margin of safety before the need to raise new capital arises. The metric aggregates cash and equivalents, determining the company's ability to fund current expenses. For Galecto, Inc. (GLTO), this is critical during the development of fibrosis inhibitors. The monopoly on biologics requires significant investment prior to commercialization.